Related Experiment Videos
Lp(a) lipoprotein is a major risk factor for cardiovascular disease: pathogenic mechanisms and clinical significance
1Department of Clinical Chemistry, University of Umeå, Sweden.
Insights
Lipoprotein(a) (Lp(a)) is a significant risk factor for atherosclerosis and heart disease in middle-aged individuals. Managing cholesterol levels is crucial for those with high Lp(a) to reduce heart attack risk.
Area of Science:
- Cardiology
- Biochemistry
- Preventive Medicine
Background:
- Lipoprotein(a) (Lp(a)) is increasingly recognized as a critical independent risk factor for atherosclerosis and coronary heart disease.
- Conventional risk factors for cardiovascular disease do not fully capture an individual's risk profile.
- Understanding the role of Lp(a) in conjunction with other biomarkers is essential for accurate risk assessment.
Purpose of the Study:
- To evaluate the clinical significance of lipoprotein(a) (Lp(a)) as a risk factor for atherosclerosis and coronary heart disease across multiple studies.
- To investigate the synergistic effects of Lp(a) with cholesterol and other factors in predicting acute myocardial infarction.
- To assess the protective role of apolipoprotein A-I (apo A-I) and the impact of low-density lipoprotein cholesterol (LDL-C) levels in individuals with elevated Lp(a).
Main Methods:
- Analysis of data from two previous and two recent studies involving middle-aged males and females.
- Inclusion of conventional and novel risk factors, with varying Lp(a) quantification methods.
- Application of multivariate logistic regression analysis to identify significant predictors of cardiovascular events.
Main Results:
- Lipoprotein(a) (Lp(a)) was consistently identified as a significant risk factor for cardiovascular disease in all four studies.
- A synergistic effect between Lp(a) and cholesterol was observed, predicting acute myocardial infarction in Swedish males (cholesterol > 6.5 mmol/l and Lp(a) > 200 mg/l).
- Elevated Lp(a) (> 500 mg/l) and high LDL-C (> 130 mg/dl) were significant risk factors in US women, while high apo A-I showed a protective effect in both sexes.
Conclusions:
- Lipoprotein(a) (Lp(a)) levels are valuable for identifying individuals at high risk for cardiovascular events.
- Managing low-density lipoprotein cholesterol (LDL-C) to below 100 mg/dl (<2.6 mmol/l) is a key strategy for high-risk individuals with elevated Lp(a).
- Further research into potential associations, such as with Chlamydia pneumoniae infection, may provide additional insights into Lp(a) pathophysiology.
Abstract:
The results of two previous and two recent studies of middle-aged males and females are presented to exemplify the clinical importance of lipoprotein(a) (Lp(a)) as a risk factor for atherosclerosis and coronary heart disease. In these studies various conventional and recently suggested risk factors were included and different methods for Lp(a) quantification were used. Lp(a) was a significant risk factor in all four studies. In the recent prospective case-control study, Lp(a) and cholesterol were found to act synergistically and predict primary acute myocardial infarction in Swedish males. A cholesterol level above 6.5 mmol/l increased the risk of acute myocardial infarction if the Lp(a) level was above 200 mg/l. The plasma apo A-I level was a protective factor. In the other recent case-control study, an Lp(a) level above 500 mg/l was a highly significant risk factor in Black and White US women with myocardial infarction or advanced coronary artery disease in addition to low density lipoprotein cholesterol levels above 130 mg/dl. A high apo A-I level was a protective factor. In these studies no other factors tested reached significance in multivariate logistic regression analysis. A hypothetical association between high Lp(a) levels and intracellular infection with Chlamydia pneumoniae is discussed. The results suggest that the Lp(a) level is useful in identifying high-risk individuals. Lowering low density lipoprotein cholesterol below 100 mg/dl (<2.6 mmol/l) seems to be most important in both males and females with high-risk Lp(a) levels.